PF1801 for Polymyositis Earns Orphan Drug Status
Sometimes, it can be difficult to spur drug development for rare or life-threatening diseases, considering the number of patients. To address this, and improve patient outcomes, the FDA developed the…
Sometimes, it can be difficult to spur drug development for rare or life-threatening diseases, considering the number of patients. To address this, and improve patient outcomes, the FDA developed the…